On January 30, 2019, Abivax hosted a KOL lunch event focused on promising clinical development of ABX464 in Ulcerative Colitis and HIV.
A replay of the webcast is available here: http://abivax.streameo.fr/live.html
Goetz Partners:Chris Redhead
NIBC:Dylan van Haaften & Anita Ye
Royal Bank of Canada:Douglas Miehm
LifeSci Capital:David Sherman & Sam Slutsky
Chris Maggos LifeSci Advisors Chris@lifesciadvisors.com +41 79 367 6254